Arbutus Biopharma Corporation - Common Stock (ABUS)

In a landmark resolution that removes a multi-year shadow over the messenger RNA (mRNA) industry, Moderna, Inc. (NASDAQ:MRNA) has reached a comprehensive $2.25 billion global settlement with Genevant Sciences and Arbutus Biopharma (NASDAQ:ABUS). Announced on March 3, 2026, the deal concludes one of the most contentious patent

The news is likely to come as a relief to many investors, Citi told investors in a research note.

The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines.

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.

As of January 16, 2026, Moderna, Inc. (NASDAQ: MRNA) stands at a critical crossroads. Once the poster child for the biotechnology industry’s rapid response to a global pandemic, the Cambridge-based pioneer is currently undergoing a painful but essential metamorphosis. The "mRNA 1.0" era, defined by the singular success of its COVID-19 vaccine, has effectively ended. [...]

Once the poster child for the biotechnology sector’s rapid response to the global pandemic, Moderna, Inc. (Nasdaq: MRNA) finds itself at a critical crossroads in early 2026. After a tumultuous period characterized by a sharp decline from its 2021 peak market valuation of nearly $190 billion, the Cambridge-based pioneer is working to convince a skeptical [...]

After a strong start to 2023, the virology-focused biopharma company has hit a regulatory speed bump.

As the 44th Annual J.P. Morgan Healthcare Conference concludes in early January 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a critical crossroads. Once the darling of the pandemic era, the biotechnology giant is now grappling with a stock price that has settled into a volatile range between $33.

Today’s Date: January 9, 2026 Introduction As we enter the first weeks of 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a defining crossroads. Once the poster child for the biotech boom of the early 2020s, the Cambridge-based pioneer has spent the last 24 months attempting to shed its image as a "pandemic-only" play. After [...]

Arbutus Biopharma (ABUS) shows strong technical health and high-growth momentum, with surging sales and earnings, positioning it for potential gains.

Alnylam Pharmaceuticals has conceded that Moderna's products do not infringe on its patents, as a court ruling determined. Both companies have agreed to dismiss the case without prejudice for possible future actions.

While the Arbutus layoffs represents a major overhaul operationally, the market has responded positively to ABUS stock. Here’s why.

ABUS stock results show that Arbutus Biopharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

The healthcare industry is one of the most potent yet also one of the most competitive. This has short sellers out for blood.

Delaware Judge favors Arbutus and Genevant Sciences in their patent dispute with Moderna over COVID-19 vaccine technology.

Moderna stock falls 2.32% due to patent infringement suit. However, some investors see this as an opportunity to enter or average out. Golden Cross formation also offers hope for future growth.

Arbutus Biopharma soared more than 20% on Wednesday, April 3, after the company received permission to pursue a claim against Moderna in court.

Biotech firm Promosome has agreed to end the lawsuit, which accused the COVID-19 vaccine manufacturers, Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX), of patent infrin